IDYA
IDEAYA Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$38.41
−0.52%Year over year
Reported trailing growth
- Revenue
- +3244.7%
- EBITDA
- +37.2%
- EBIT
- +43.5%
- EPS
- +49.3%
- Free cash flow
- +36.1%
- Operating cash flow
- +36.4%
Forward estimates
Based on analyst estimates
- Revenue
- -77.7%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +62.5%
- EBITDA
- +42.8%
- EBIT
- +51.3%
- Net income
- +58.6%
- EPS
- +61.9%
- Free cash flow
- +70.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026